A phase 1 trial evaluated nivolumab, an anti-programmed cell death-1 (PD-1) inhibitor, in the treatment of patients with advanced cancers (NCT00730639) and found no significant objective response rates (ORRs) among those with PC[56,57]. This evidence concerns the gene PDCD1 and cancer.